BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30696697)

  • 1.
    Colebatch AJ; Dobrovic A; Cooper WA
    J Clin Pathol; 2019 Apr; 72(4):281-284. PubMed ID: 30696697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of TERT promoter mutations in human cancers.
    Vinagre J; Almeida A; Pópulo H; Batista R; Lyra J; Pinto V; Coelho R; Celestino R; Prazeres H; Lima L; Melo M; da Rocha AG; Preto A; Castro P; Castro L; Pardal F; Lopes JM; Santos LL; Reis RM; Cameselle-Teijeiro J; Sobrinho-Simões M; Lima J; Máximo V; Soares P
    Nat Commun; 2013; 4():2185. PubMed ID: 23887589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
    Li C; Wu S; Wang H; Bi X; Yang Z; Du Y; He L; Cai Z; Wang J; Fan Z
    Oncotarget; 2015 Aug; 6(23):19542-51. PubMed ID: 26143634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
    Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
    Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
    Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
    Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT biology and function in cancer: beyond immortalisation.
    Pestana A; Vinagre J; Sobrinho-Simões M; Soares P
    J Mol Endocrinol; 2017 Feb; 58(2):R129-R146. PubMed ID: 28057768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters.
    Li Y; Tergaonkar V
    Transcription; 2016 Mar; 7(2):44-9. PubMed ID: 27028424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of the TERT promoter and its impact on human cancer.
    Lee DD; Komosa M; Nunes NM; Tabori U
    Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.
    Kumar M; Witt B; Knippschild U; Koch S; Meena JK; Heinlein C; Weise JM; Krepulat F; Kuchenbauer F; Iben S; Rudolph KL; Deppert W; Günes C
    Int J Cancer; 2013 May; 132(9):2032-43. PubMed ID: 23023397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase Biology Associations Offer Keys to Cancer and Aging Therapeutics.
    Smith-Sonneborn J
    Curr Aging Sci; 2020; 13(1):11-21. PubMed ID: 31544708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.
    Min J; Shay JW
    Cancer Discov; 2016 Nov; 6(11):1212-1214. PubMed ID: 27807101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of telomerase in cancer.
    Akincilar SC; Unal B; Tergaonkar V
    Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding TERT Promoter Mutations: A Common Path to Immortality.
    Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
    Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.
    Liu Z; Li Q; Li K; Chen L; Li W; Hou M; Liu T; Yang J; Lindvall C; Björkholm M; Jia J; Xu D
    Oncogene; 2013 Sep; 32(36):4203-13. PubMed ID: 23045275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.